Back to homepage

Tag "hypoglycaemic agents"

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin

Authors: Andrew Ahmann

Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose cotransporter 2 (SGLT2) inhibitors are an emerging class of antidiabetes agents with an insulin-independent mechanism of action, making them suitable for use in combination with any other class of antidiabetes agents, including insulin. In this review the evaluates a 78-week, randomized, double-blind, placebo controlled trial investigating the impact of empagliflozin, an SGLT2 inhibitor, as add-on to basal insulin in patients with inadequate glycemic control on basal insulin, with or without metformin and/or a sulfonylurea.

More

A review of current treatment strategies for gestational diabetes mellitus

Authors: Kristi W Kelley, Dana G Carroll, Allison Meyer

Once changes in lifestyle have failed, treatment for gestational diabetes mellitus remains a matter of debate. In this article the authors review the evidence for glyburide and metformin, and discuss the role of insulin. Also, recommendations for postpartum screening and how to manage patients who are breastfeeding are described.

More